| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Basic Science Investigations |
vß3-Integrin Expression
1 PET Imaging Science Center, Keck School of Medicine, University of Southern California, Los Angeles, California
2 Department of Pediatrics, Children’s Hospital Los Angeles, Los Angeles, California
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
v-integrins, cell adhesion molecules that are highly expressed on activated endothelial cells and tumor cells but not on dormant endothelial cells or normal cells, present an attractive target for tumor imaging and therapy. We previously coupled a cyclic Arg-Gly-Asp (RGD) peptide, c(RGDyK), with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) and labeled the RGD-DOTA conjugate with 64Cu (half-life, 12.8 h; 19% ß+) for solid tumor targeting, with high tumor-to-background contrast. The rapid tumor washout rate and persistent liver and kidney retention of this tracer prompted us to optimize the tracer for improved pharmacokinetic behavior. In this study, we introduced a polyethylene glycol (PEG; molecular weight, 3,400) moiety between DOTA and RGD and evaluated the 64Cu-DOTA-PEG-RGD tracer for microPET imaging in brain tumor models. Methods: DOTA was activated in situ and conjugated with RGD-PEG-NH2 under slightly basic conditions. vß3-Integrin-binding affinity was evaluated with a solid-phase receptor-binding assay in the presence of 125I-echistatin. Female nude mice bearing subcutaneous U87MG glioblastoma xenografts were administered 64Cu-DOTA-PEG-RGD, and the biodistributions of the radiotracer were evaluated from 30 min to 4 h after injection. microPET (20 min of static imaging at 1 h after injection) and then quantitative autoradiography were used for tumor visualization and quantification. The same tracer was also applied to an orthotopic U87MG model for tumor detection. Results: The radiotracer was synthesized with a high specific activity (14,800–29,600 GBq/mmol [400–800 Ci/mmol]). The c(RGDyK)-PEG-DOTA ligand showed intermediate binding affinity for vß3-integrin (50% inhibitory concentration, 67.5 ± 7.8 nmol/L [mean ± SD]). The pegylated RGD peptide demonstrated rapid blood clearance (0.57 ± 0.15 percentage injected dose [%ID]/g [mean ± SD] at 30 min after injection and 0.03 ± 0.02 %ID/g at 4 h after injection). Activity accumulation in the tumor was rapid and high at early time points (2.74 ± 0.45 %ID/g at 30 min after injection), and some activity washout was seen over time (1.62 ± 0.18 %ID/g at 4 h after injection). Compared with 64Cu-DOTA-RGD, this tracer showed improved in vivo kinetics, with significantly reduced liver uptake (0.99 ± 0.08 %ID/g vs. 1.73 ± 0.39 %ID/g at 30 min after injection and 0.58 ± 0.07 %ID/g vs. 2.57 ± 0.49 %ID/g at 4 h after injection). The pegylated RGD peptide showed higher renal accumulation at early time points (3.51 ± 0.24 %ID/g vs. 2.18 ± 0.23 %ID/g at 30 min after infection) but more rapid clearance (1.82 ± 0.29 %ID/g vs. 2.01 ± 0.25 %ID/g at 1 h after injection) than 64Cu-DOTA-RGD. The integrin receptor specificity of this radiotracer was demonstrated by blocking of tumor uptake by coinjection with nonradiolabeled c(RGDyK). The high tumor-to-organ ratios for the pegylated RGD peptide tracer (at 1 h after injection: tumor-to-blood ratio, 20; tumor-to-muscle ratio, 12; tumor-to-liver ratio, 2.7; and tumor-to-kidney ratio, 1.2) were confirmed by microPET and autoradiographic imaging in a subcutaneous U87MG tumor model. This tracer was also able to detect an orthotopic brain tumor in a model in which U87MG cells were implanted into the mouse forebrain. Although the magnitude of tumor uptake in the orthotopic xenograft was lower than that in the subcutaneous xenograft, the orthotopic tumor was still visualized with clear contrast from normal brain tissue. Conclusion: This study demonstrated the suitability of a PEG moiety for improving the in vivo kinetics of a 64Cu-RGD peptide tracer without compromising the tumor-targeting ability and specificity of the peptide. Systematic investigations of the effects of the size and geometry of PEG on tumor targeting and in vivo kinetics will lead to the development of radiotracers suitable for clinical applications such as visualizing and quantifying v-integrin expression by PET. In addition, the same ligand labeled with therapeutic radionuclides may be applicable for integrin-targeted internal radiotherapy.
Key Words: molecular imaging • PET • radiopharmaceuticals • angiogenesis • integrin • Arg-Gly-Asp • 64Cu • pegylation
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
vß3-integrin and vß5-integrin, which are highly expressed on activated endothelial cells and tumor cells but not on quiescent vessels and normal cells (12). The expression of vß3-integrin is required for angiogenesis induced by fibroblast growth factor 2 and tumor necrosis factor , and the expression of vß5-integrin is required for angiogenesis induced by vascular endothelial growth factor and transforming growth factor (13). Monoclonal antibodies, peptides, and peptidomimetic antagonists of v-integrins have been shown to block angiogenesis in both preclinical tumor models and phase I and II clinical trials by inhibiting endothelium-specific integrin survival signaling (14,15). The ability to noninvasively visualize and quantify the v-integrin expression level during tumor growth and spread as well as during anti-integrin treatment will provide new opportunities to develop individualized therapeutic approaches, to select appropriate patients entering clinical trials for anti-integrin treatment, to establish optimized dosages and dose intervals for effective treatment on the basis of receptor occupancy studies, to detect early antiangiogenic responses and quantitatively evaluate treatment efficacy, and finally to cooptimize imaging and therapy via structure–activity studies.
Arg-Gly-Asp (RGD) peptide antagonists of v-integrins have been labeled with different radionuclides for both imaging and therapeutic purposes. Notably, various investigators (16–20) labeled cyclic RGD peptides with 18F (half-life [t1/2], 119.7 min; 99% ß+) for microPET imaging in various solid tumor models, and high tumor-to-background contrast was obtained. However, these radiotracers have some drawbacks: the labeling procedure is tedious and relatively inefficient, tumor uptake is modest, and tumor retention time is short. Although the tracers were able to localize v-integrin-positive tumors, their utility in reflecting targeted radiotherapy is limited because no therapeutic fluorine isotope is available. Because of the existence of an imaging and therapy radionuclide pair (64Cu/67Cu) for diagnosing and treating cancer, 64Cu-labeled RGD peptides with successful tumor-targeting properties will eventually be able to determine dosimetry and tumor responses to the same ligand labeled with therapeutic amounts of 67Cu for v-integrin-mediated internal radiotherapy.
Chen et al. (21) recently described the synthesis of a 64Cu-labeled RGD peptide and microPET imaging of orthotopic MDA-MB-435 breast cancer tumor xenografts, with high tumor-to-contralateral background contrast. However, this tracer also had a rapid tumor washout rate and showed persistent activity accumulation in the liver and kidneys. The unfavorable in vivo pharmacokinetics of this tracer limit the application of a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-RGD conjugate for tumor imaging and radiotherapy. Haubner et al. (22) chose to modify the RGD peptide with a glycosylate moiety to increase hydrophilicity and thus reduce blood clearance and reduce hepatobiliary excretion. We have found that polyethylene glycol (PEG) is a suitable tool for modifying the RGD peptide, with improved in vivo kinetics.
Chen et al. (23) recently modified a cyclic RGD peptide, c(RGDyK), by introducing a monomethoxy PEG moiety (mPEG; molecular weight [MW], 2,000) into the lysine 
-amino group. The resulting RGD-mPEG conjugate showed drastically decreased renal uptake and slightly increased liver accumulation compared with the parental RGD peptide. In this study, we inserted a heterobifunctional PEG linker (MW, 3,400) between DOTA and c(RGDyK). The resulting DOTA-PEG-RGD conjugate then was radiolabeled with 64Cu (t1/2, 12.8 h; 19% ß+) for microPET imaging studies with both subcutaneous and orthotopic U87MG glioblastoma models.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
Chromalux HB microplates were obtained from Dynex Technologies. 125I-Echistatin, labeled by the lactoperoxidase method to a specific activity of 74,000 GBq/mmol (2,000 Ci/mmol), was obtained from Amersham Biosciences. Echistatin was purchased from Sigma. Purified human vß3-integrin in a Triton X-100 formulation was obtained from Chemicon International.
Semipreparative reversed-phase high-pressure liquid chromatography (HPLC) was accomplished by use of a Waters 515 chromatography system with a 486 tunable absorbance detector. Purification was performed with a Vydac 218TP510 protein and peptide column (5 µm; 250 x 10 mm). The flow rate was 5 mL/min; the mobile phase was changed from 95% solvent A (0.1% TFA in water) and 5% solvent B (0.1% TFA in acetonitrile) (0–2 min) to 35% solvent A and 65% solvent B at 32 min. The analytic HPLC method was performed with the same gradient system but with a Vydac 218TP54 column (5 µm; 250 x 4.6 mm) and a flow rate of 1 mL/min. The absorbance was monitored at 218 nm. Radio–thin-layer chromatography (TLC) was performed by use of MKC18F plates (Whatman), Bioscan System 200, and Winscan software (version 2.2; BioScan Inc.). Reversed-phase extraction C18 SepPak cartridges were obtained from Waters.
Preparation of DOTA-PEG-RGD Conjugate
DOTA was activated in situ by EDC at a molar ratio for DOTA:EDC:SNHS of 10:5:4 (21). RGD-PEG conjugate (8 mg; 2 µmol) dissolved in 1,600 µL of water (5 mg/mL) was cooled to 4°C and added to a DOTA-sulfosuccinimydyl ester (OSSu) reaction mixture (10 µmol; calculated on the basis of SNHS), and the pH was adjusted to 8.5 with 1N NaOH. The reaction mixture was incubated overnight at 4°C. DOTA-PEG-RGD conjugate was purified by semipreparative HPLC. The sample containing the RGD conjugate was collected, lyophilized, and dissolved in H2O at a concentration of 1 mg/mL for use in radiolabeling reactions.
64Cu Radiolabeling
DOTA-PEG-RGD was labeled with 64Cu by the addition of 37–185 MBq (1–5 mCi) of 64Cu (5–25 µg of DOTA-PEG-RGD per 37 MBq of 64Cu) in 0.1N sodium acetate (pH 5.5) buffer and 45 min of incubation at 50°C. The reaction was terminated by the addition of 5 µL of ethylenediaminetetraacetic acid solution (10 mmol/L). The radiochemical yield was determined by radio-TLC with MKC18F TLC plates as the stationary phase and methanol:10% sodium acetate (70:30) as the eluent. 64Cu-DOTA-PEG-RGD was purified by use of a C18 SepPak cartridge with 85% ethanol as the elution solvent. Radiochemical purity was determined by radio-TLC or radio-HPLC. The ethanol was evaporated, the activity was reconstituted with phosphate-buffered saline, and the sample was passed through a 0.22-µm Millipore filter into a sterile multidose vial for use in animal experiments.
Octanol–Water Partition Coefficient
About 370 kBq of 64Cu-DOTA-c(RGDyK) or 64Cu-DOTA-PEG-c(RGDyK) in 500 µL of saline were added to 500 µL of octanol in an Eppendorf microcentrifuge tube (Brinkman). The 2 layers were mixed for 10 min at room temperature, the tube was centrifuged at 14,000 rpm for 5 min (model 5415C Eppendorf microcentrifuge; Brinkman), and the counts in 100-µL aliquots of both organic and inorganic layers were determined by use of a 
-counter (Packard). The experiment was repeated 3 times.
Solid-Phase Receptor-Binding Assay
The standard assay was performed as described previously with modifications (26). Microtiter-2 96-well plates (Dynatech Laboratories, Inc.) were coated with vß3-integrin (500 ng/mL; 100 µL per well) in coating buffer (Tris-HCl [pH 7.4] at 25 mmol/L, NaCl at 150 mmol/L, CaCl2 at 1 mmol/L, MgCl2 at 0.5 mmol/L, and MnCl2 at 1 mmol/L) for 16 h at 4°C. The wells then were blocked for 2 h with 200 µL of blocking buffer (coating buffer with 1% radioimmunoassay-grade bovine serum albumin). The plates then were washed twice with binding buffer (coating buffer with 0.1% bovine serum albumin) and incubated with 125I-echistatin (0.06 nmol/L) in the presence of various concentrations of RGD peptide (0.1 nmol/L–5 µmol/L) at room temperature for 3 h. After incubation, the plates were washed 3 times with binding buffer, and the radioactivity was solubilized with 2N boiling NaOH and subjected to -counting. Nonspecific binding of 125I-echistatin to vß3-integrin was determined in the presence of echistatin at 100 nmol/L. The 50% inhibitory concentrations were calculated by nonlinear regression analysis by use of the GraphPad Prism computer fitting program (GraphPad Software, Inc.). Each data point represents the average value for triplicate wells.
Biodistribution Studies
Animal experiments were conducted under a protocol approved by the University of Southern California Institutional Animal Care and Use Committee. Female athymic nude mice (nu/nu) obtained from Harlan at 4–6 wk of age were injected subcutaneously in the right front leg with 5 x 106 U87MG glioblastoma cells suspended in 150 µL of Eagle’s minimum essential medium. When the tumors reached 0.4–0.6 cm in diameter (14–18 d after implantation), the mice were used for biodistribution and microPET imaging experiments.
Details of the orthotopic (intracranial) xenotransplant model in nu/nu mice were described previously (27). In brief, 105 U87MG tumor cells in 1 µL of RPMI medium were injected through a 33-gauge injection needle over 10 min into the nude mouse (4–6 wk old) forebrain 1.5 mm lateral and 0.5 mm anterior to the bregma and at a depth of 2.5 mm by use of a continuous infusion pump. The needle was removed, the burr hole was closed with bone wax, and the skin incision was closed with dermal glue. Mice were kept under ketamine–xylazine anesthesia during the procedure. This tumor cell number resulted in the growth of tumors in all experimental animals and a highly reproducible growth rate. At 5 wk after injection, when the tumors reached 3 mm or more in diameter, the mice were used for microPET imaging studies.
Nude mice bearing subcutaneously xenografted human U87MG glioblastoma tumors were injected intravenously with approximately 370 kBq (10 µCi) of 64Cu-DOTA-PEG-RGD. Animals were euthanized at 30 min, 1 h, 2 h, and 4 h after injection. Blood, tumors, and major organs and tissues were collected and wet weighed, and counts were determined by use of a -counter. The percentage injected dose per gram (%ID/g) was determined for each sample. For each mouse, the radioactivity in the tissue samples was calibrated against a known quantity of the injected compound. Values are reported as mean ± SD for groups of 4 animals. The receptor-mediated localization of the radiotracer was investigated by injection of 64Cu-DOTA-PEG-RGD with c(RGDyK) at 10 mg/kg in a subcutaneous U87MG tumor model. Biodistributions were determined as described above at 1 h after injection for 4 mice per group.
microPET Imaging
PET was performed by use of a microPET R4 rodent model scanner (Concorde Microsystems Inc.). The scanner has a computer-controlled bed and 10.8-cm transaxial and 8-cm axial fields of view. It has no septa and operates exclusively in the 3-dimensional list mode. All raw data were first sorted into 3-dimensional sinograms; this step was followed by Fourier rebinning and 2-dimensional (2D) filtered backprojection image reconstruction by use of a ramp filter with the Nyquist limit (0.5 cycle per voxel) as the cutoff frequency. For the subcutaneous tumor model, each mouse was injected with 14.8 MBq (400 µCi) of 64Cu-DOTA-PEG-RGD via the tail vein, sacrificed at 1 h after injection by cervical dislocation under ketamine–xylazine anesthesia, and placed near the center of the field of view of the microPET scanner, where the highest image resolution and sensitivity are available. The mouse was scanned for 20 min and then subjected to whole-body autoradiography. The raw data were framed into one static frame without attenuation correction. For the orthotopic U87MG tumor model, a 20-min static image was obtained at 1 h after injection. The brain tumor was excised postmortem, fixed in buffered formalin, and embedded in paraffin for hexatoxylin–eosin staining.
Autoradiography
Autoradiography was performed by use of a Packard Cyclone Storage Phosphor Screen system and a Bright 5030/WD/MR cryomicrotome (Hacker Instruments). Immediately after microPET scanning, the sacrificed mice with subcutaneous U87MG tumors were frozen in a dry ice–isopropyl alcohol bath for 2 min. The bodies then were embedded in 4% carboxymethylcellulose (Aldrich) in water by use of a stainless steel mold. The mold was placed in the dry ice–isopropyl alcohol bath for 5 min and then into a –20°C freezer for 1 h. The walls of the mold were removed, and the frozen block was mounted in the cryomicrotome. The block was cut into sections of 50 µm, and the desired sections were digitally photographed and captured for autoradiography. The sections were transferred into a chilled film cassette containing a Packard Super Resolution Screen (spatial resolution, 0.1 mm) and kept there overnight at –20°C. Screens were laser scanned by use of the Packard Cyclone system.
Statistical Analysis
The data were expressed as mean ± SD. A 1-way ANOVA was used for statistical evaluation. Means were compared by use of the Student t test. A P value of <0.05 was considered significant.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
98% when 5, 10, 15, and 20 µg of peptide per 37 MBq of 64Cu were used. The specific activity of 64Cu-DOTA-PEG-RGD ranged from 14,800 to 29,600 GBq/mmol (400–800 Ci/mmol).
|
vß3-integrin, a competitive displacement study was performed (Fig. 2). The binding of 125I-echistatin to vß3-integrin was competed for by cold echistatin, c(RGDyK), c(RGDyK)-DOTA, and c(RGDyK)-PEG-DOTA in a concentration-dependent manner. All of the peptides were able to fully suppress the binding of the radioligand to purified human vß3-integrin. The concentrations required for half-maximal competition (50% inhibitory concentrations) were calculated to be 1.01 ± 0.23 nmol/L for echistatin, 30.3 ± 5.8 nmol/L for c(RGDyK), 31.2 ± 7.4 nmol/L for c(RGDyK)-DOTA, and 67.5 ± 10.5 nmol/L for c(RGDyK)-PEG-DOTA. Both the lead compound c(RGDyK)-DOTA and the pegylated analog c(RGDyK)-PEG-DOTA showed high hydrophilicity, as indicated from octanol–water partition coefficient measurements. LogP values for c(RGDyK)-DOTA and c(RGDyK)-PEG-DOTA were –2.8 ± 0.04 and –2.97 ± 0.30, respectively.
|
|
|
|
v-integrin expression.
|
microPET imaging was also successful in visualizing an orthotopic U87MG glioblastoma implanted into the mouse forebrain (Fig. 7). Although the absolute tumor uptake (0.4 ± 0.1 %ID/g) was significantly lower than that of the subcutaneous tumor, the tumor-to-brain ratio still reached 4.0 ± 0.5 because of the extremely low background activity accumulation in the normal brain tissue. Histologic staining of the mouse brain (Fig. 8) removed at the end of the scan confirmed the presence and location of the U87MG tumor, which measured 2.9 x 2.8 mm.
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
The overexpression of v-integrins (vß3 and vß5) on solid tumor cells and activated endothelial cells has aroused interest in the development of radiolabeled RGD peptides for imaging and therapy of cancer. Various investigators have shown that 18F-labeled RGD peptides can accumulate in different tumors, such as breast cancer (16,20), brain tumor (17,23), and melanoma and osteosarcoma (18,19). However, the introduction of a prosthetic 4-18F-fluorobenzoyl group to the lysine side chain -amino group resulted in unfavorable hepatobiliary excretion, as indicated by high uptake in the gallbladder and intestines; this situation may hamper the imaging of tumor lesions located in the lower abdomen and limit the activity dose that can be administered safely because of whole-body radiation exposure. Haubner et al. demonstrated that substituting a hydrophilic sugar moiety for the lysine resulted in predominant renal clearance for both 125I-labeled (22) and 18F-labeled (18,19) glycosylated RGD peptides. On the other hand, we found that the tumor-targeting ability and in vivo kinetics of an RGD peptide could be substantially improved by introducing a PEG moiety into the lysine side chain amino group. We coupled a c(RGDyK) peptide with mPEG (MW, 2,000) and labeled the c(RGDyK)-mPEG conjugate with 125I. The pegylated RGD peptide resulted in faster blood clearance and lower kidney uptake, without compromising the receptor-targeting ability, than c(RGDyK) (23). We also found that 18F-labeled pegylated RGD (PEG MW, 3,400) resulted in a longer tumor retention time and far less hepatobiliary excretion than the corresponding 18F-labeled RGD (24).
Because no therapeutic fluorine isotope is available, 18F-labeled RGD peptides will not be able to provide direct dosimetry information for integrin-targeted internal radiotherapy. 64Cu with 19% positron emission and 40% ß-emission (maximum energy, 578 keV) efficiencies has the potential for both PET and therapy. Chen et al. previously conjugated c(RGDyK) with macrocyclic chelator DOTA and labeled the DOTA-RGD conjugate with 64Cu for PET of breast cancer tumors (21). This tracer showed significant liver uptake. Recent metabolic studies of 111In-diethylenetriaminepentaacetic acid (DTPA)-conjugated polypeptides indicated that when DTPA was attached to the lysine of the polypeptides, a 111In-DTPA adduct of lysine was generated as the final radiometabolite after lysosomal proteolysis of the parental peptides in the liver (29). We assume that the prominent liver retention after intravenous administration of 64Cu-DOTA-RGD seen here may be ascribed to the combined effects of the transchelation of 64Cu from DOTA to superoxide dismutase (30) in the liver and the persistent localization of the final radiometal metabolite 64Cu-DOTA-lysine within the tissue. Therefore, the practical use of 64Cu as an imaging and therapeutic isotope relies on the development of new chelating agents for Cu(II) that have greater kinetic stability as well as on the prevention of the delivery of negatively charged metabolites to liver nonparenchymal cells via scavenger receptor-mediated endocytosis (31).
Intrigued by the ability of pegylation to improve the tumor-targeting and in vivo kinetics of both 125I- and 18F-labeled RGD peptides, we extended our study to observe the impact of pegylation on 64Cu-DOTA-RGD. The results of an isolated, immobilized integrin receptor-binding assay indicated that introduction of the PEG moiety at the lysine side chain amino group had a modest influence on vß3-integrin affinity and selectivity. All of the RGD peptide ligands bound vß3-integrin with a significantly lower affinity than echistatin, which is folded in a series of irregular loops to form a rigid core stabilized by 4 disulfide bridges (32). It is also worth noting that the introduction of a PEG moiety with an MW of 3,400 significantly reduced the circulatory t1/2 of the pegylated radiotracer, in contrast to the results reported for many other pegylated proteins and polypeptides (33). Since the octanol–water partition coefficients of the cyclic RGD peptide and pegylated RGD peptide tracers were similar, the more rapid blood clearance of the pegylated RGD peptide could have been attributable to the fact that this compound showed reduced interactions with blood elements (plasma proteins or blood cells) rather than changes in hydrophilicity on modification.
Both 64Cu-DOTA-RGD and 64Cu-DOTA-PEG-RGD were cleared rapidly from the kidneys. In general, PEG shows little toxicity and is eliminated from the body intact either by the kidneys (for PEG of <30 kDa) or in the feces (for PEG of >20 kDa) (34–36); subsequent reabsorption occurs in the proximal tubular cells, where the pegylated peptide is internalized and degraded in the lysosomes. Following this pathway, the main radiolabeled catabolite of 64Cu-DOTA-PEG-RGD probably is 64Cu-DOTA-PEG-Lys. 64Cu-DOTA-Lys and 64Cu-DOTA-PEG-Lys have the same overall negative charge (–1), but 64Cu-DOTA-PEG-RGD had significantly lower liver uptake and more rapid liver clearance. We assume that the PEG polymer, along with the associated water molecules, acts like a shield to wrap the 64Cu-DOTA chelate and reduces the apparent negative charge, and the negative charge density thus reduces the apparent affinity of the radiometal metabolite for hepatic scavenger receptors. This notion agrees with the phenomenon in which an increase in the negative charge density of proteins by acylation efficiently increases liver uptake (37).
The features of rapid blood and renal clearance and limited hepatic and biliary excretion permit high signal-to-noise ratios for in vivo imaging soon after injection (1 h). The activities quantified in the mouse tumor, liver, and kidneys were comparable to those obtained by the direct tissue sampling technique. microPET imaging used with the orthotopic U87MG tumor model revealed a good tumor-to-brain ratio; the magnitude of uptake of the orthotopic tumor was about 5 or 6 times lower than that of the subcutaneous tumor. Whether the blood–brain barrier or different integrin expression characteristics of orthotopic brain tumors and subcutaneous tumors are responsible for this difference in uptake needs to be investigated further.
The receptor specificity of the RGD peptide was not significantly affected by the introduction of a PEG moiety and a 64Cu-DOTA radiolabel, because of the invariance of the "kinked" conformation of the pentapeptide (38). The unaltered tumor uptake and clearance and the favorable biokinetics make this radiopharmaceutical suitable for PET of solid tumors that overexpress v-integrin and for integrin-targeted internal radiotherapy when therapeutic amounts of 64Cu- or 67Cu-labeled pegylated RGD peptide are applied. A radionuclide with PET and therapeutic capacities, such as 64Cu, could be very advantageous, because accurate individualized dosimetry could be obtained for each patient with PET before radiotherapy. The DOTA-PEG-RGD conjugate could also be used with 86Y (t1/2, 14.7 h; 33% ß+) as a surrogate marker to detect the uptake and dosimetry of 90Y-labeled RGD.
We recognize that 2 important issues remain unresolved. The first issue is whether the magnitude of tumor uptake obtained from PET correlates well with the tumor integrin expression level. The ability to measure tumor integrin receptor density noninvasively could have great value in predicting the effectiveness of RGD peptide therapy in patients with brain tumors and other solid tumors that express v-integrins. Our recent quantitative analysis of tracer kinetics with the reference tissue sampling technique, which assumes that the radiolabel is not irreversibly trapped within the reference region and that the rate of turnover of the exchanging spaces in both the tumor and the reference tissue is rapid compared with the duration of the time–activity curves (X. Chen, P.S. Conti, unpublished data, 2003), has suggested the feasibility of this reference method (39) for quantifying v-integrin receptor density during tumor growth and in response to competition from a nonlabeled RGD peptide or anti-integrin drugs targeted to v-integrins. Our future studies will focus on the validation of the results of such an analysis with traditional Western blots and in vitro receptor autoradiography.
The second issue is whether the tumor retention of a suitably labeled RGD peptide is attributable to interactions with v-integrins expressed on the neovasculature, on the tumor cells, or on a combination of both cell types. The intrinsic resolution of PET will not allow this question to be answered directly. In this regard, it is possible that further advances in molecular biology may elucidate subclasses of v-integrins present on endothelial cells versus tumor cells, thereby providing an approach for developing more specific diagnostic and therapeutic ligands in the future. In the interim, existing agents may be used to assess overall v-integrin activity in tumors.
|
CONCLUSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
v-integrin expression. This new radiotracer was directly compared with 64Cu-DOTA-RGD in vivo, and the results suggested that DOTA-PEG-RGD is a suitable ligand for labeling radiometals that can form stable complexes with the DOTA moiety for both imaging and therapeutic applications. Optimization of this tracer by systematic investigation of the impact of PEG size and geometry and the application of different RGD peptide and peptidomimetic antagonists of v-integrins and different chelating agents for Cu(II) may further improve the imaging and therapeutic potentials of the peptides.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
For correspondence or reprints contact: Peter S. Conti, MD, PhD, Department of Radiology, University of Southern California, 1510 San Pablo St., Suite 350, Los Angeles, CA 90033.
E-mail: pconti{at}usc.edu
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES |
|---|
v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Investig. 1999;103:1227–1230.[Medline]
v integrins. Science. 1995;270:1500–1502.vß3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123–131.[Medline]
v-integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs. 2002;11:1765–1774.[Medline]
vß3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781–1785.vß3 integrin related tumor imaging. Nucl Med Biol. 2003;30:1–9.[Medline]
v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41–49.[Medline]
vß3 receptor. J Pharmacol Exp Ther. 1997;283:843–853.v-integrin antagonist. Neurosurgery. 2001;48:151–157.[Medline]
-lysine as the primary metabolic and excretory product. Nucl Med Biol. 1994;21:1023–1034.[Medline]
vß3 integrin antagonists. J Med Chem. 1999;42:3033–3040.[Medline]
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  F. Kiessling, J. Huppert, C. Zhang, J. Jayapaul, S. Zwick, E. C. Woenne, M. M. Mueller, H. Zentgraf, M. Eisenhut, Y. Addadi, et al. RGD-labeled USPIO Inhibits Adhesion and Endocytotic Activity of {alpha}v{beta}3-Integrin-expressing Glioma Cells and Only Accumulates in the Vascular Tumor Compartment Radiology, November 1, 2009; 253(2): 462 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zannetti, S. Del Vecchio, F. Iommelli, A. Del Gatto, S. De Luca, L. Zaccaro, A. Papaccioli, J. Sommella, M. Panico, A. Speranza, et al. Imaging of {alpha}v{beta}3 Expression by a Bifunctional Chimeric RGD Peptide not Cross-Reacting with {alpha}v{beta}5 Clin. Cancer Res., August 15, 2009; 15(16): 5224 - 5233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Locke, M. D. Chordia, Y. Zhang, B. Kundu, D. Kennedy, J. Landseadel, L. Xiao, K. D. Fairchild, S. S. Berr, J. Linden, et al. A Novel Neutrophil-Specific PET Imaging Agent: cFLFLFK-PEG-64Cu J. Nucl. Med., May 1, 2009; 50(5): 790 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. DeNardo, R. Liu, H. Albrecht, A. Natarajan, J. L. Sutcliffe, C. Anderson, L. Peng, R. Ferdani, S. R. Cherry, and K. S. Lam 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies J. Nucl. Med., April 1, 2009; 50(4): 625 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Kimura, Z. Cheng, S. S. Gambhir, and J. R. Cochran Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects Cancer Res., March 15, 2009; 69(6): 2435 - 2442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Nothelfer, S. Zitzmann-Kolbe, R. Garcia-Boy, S. Kramer, C. Herold-Mende, A. Altmann, M. Eisenhut, W. Mier, and U. Haberkorn Identification and Characterization of a Peptide with Affinity to Head and Neck Cancer J. Nucl. Med., March 1, 2009; 50(3): 426 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. C. Boerman and W. J.G. Oyen Multimodality Probes: Amphibian Cars for Molecular Imaging J. Nucl. Med., August 1, 2008; 49(8): 1213 - 1214. [Full Text] [PDF]
|
|
|
|
|
|
W. Cai and X. Chen Multimodality Molecular Imaging of Tumor Angiogenesis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cai, K. Chen, Z.-B. Li, S. S. Gambhir, and X. Chen Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature J. Nucl. Med., November 1, 2007; 48(11): 1862 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wu, Z.-B. Li, K. Chen, W. Cai, L. He, F. T. Chin, F. Li, and X. Chen microPET of Tumor Integrin {alpha}v{beta}3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) J. Nucl. Med., September 1, 2007; 48(9): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rossin, D. Berndorff, M. Friebe, L. M. Dinkelborg, and M. J. Welch Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin J. Nucl. Med., July 1, 2007; 48(7): 1172 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, M. Jugold, E. C. Woenne, T. Lammers, B. Morgenstern, M. M. Mueller, H. Zentgraf, M. Bock, M. Eisenhut, W. Semmler, et al. Specific Targeting of Tumor Angiogenesis by RGD-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 1.5-T Magnetic Resonance Scanner Cancer Res., February 15, 2007; 67(4): 1555 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cai, T. Olafsen, X. Zhang, Q. Cao, S. S. Gambhir, L. E. Williams, A. M. Wu, and X. Chen PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an 18F-Labeled T84.66 Anti-Carcinoembryonic Antigen Diabody J. Nucl. Med., February 1, 2007; 48(2): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Cai, J. Rao, S. S. Gambhir, and X. Chen How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther., November 1, 2006; 5(11): 2624 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3 Cancer Res., October 1, 2006; 66(19): 9673 - 9681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cai, X. Zhang, Y. Wu, and X. Chen A Thiol-Reactive 18F-Labeling Agent, N-[2-(4-18F-Fluorobenzamido)Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of {alpha}v{beta}3 Integrin Expression J. Nucl. Med., July 1, 2006; 47(7): 1172 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Askoxylakis, W. Mier, S. Zitzmann, V. Ehemann, J. Zhang, S. Kramer, C. Beck, M. Schwab, M. Eisenhut, and U. Haberkorn Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells J. Nucl. Med., June 1, 2006; 47(6): 981 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Wester and H. Kessler Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? J. Nucl. Med., December 1, 2005; 46(12): 1940 - 1945. [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, X. Zhang, Z. Xiong, Z. Cheng, D. R. Fisher, S. Liu, S. S. Gambhir, and X. Chen microPET Imaging of Glioma Integrin {alpha}v{beta}3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide J. Nucl. Med., October 1, 2005; 46(10): 1707 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Askoxylakis, S. Zitzmann, W. Mier, K. Graham, S. Kramer, F. von Wegner, R. H.A. Fink, M. Schwab, M. Eisenhut, and U. Haberkorn Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160 Clin. Cancer Res., September 15, 2005; 11(18): 6705 - 6712. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
) in nude mice. Error bars denote SDs (n = 4). Sm int = small intestine.
